OncoLize awarded SME status with EMA

15th January 2025.

Leiden-based Dutch start-up OncoLize has been awarded the SME status with the European Medicinal Agency. This is the first step in accelerating their product ChemGem^TM  towards clinical trials to treat pancreatic cancer with their injectable drug depots.

OncoLize's  ChemoGell^TM platform uses liquid formulations to deliver a wide range of anti-cancer drugs in a safe, local and more effective manner, and it is suitable for both chemo- and immunotherapy.

Injected directly into a solid tumor, the OncoLize liquid formulation thickens within seconds to form a soft gel depot.The depot erodes slowly as it releases its drug cargo over days to weeks at higher concentrations inside the tumor mass. This localized method of delivery will significantly reduce the total drug load and can diminish the many side effects associated with oral or intravenous delivery of anti-cancer drugs.

For info and contacts:

www.oncolize.com

info@oncolize.com

invest@oncolize.com